Clinical Trials Logo

Locally Advanced Gastric Cancer clinical trials

View clinical trials related to Locally Advanced Gastric Cancer.

Filter by:

NCT ID: NCT06277453 Active, not recruiting - Clinical trials for Locally Advanced Gastric Cancer

Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy

Start date: January 1, 2023
Phase:
Study type: Observational

To explore the effect of adjuvant chemotherapy cycles on the prognosis of this specific patient with lymph node-negative gastric cancer following neoadjuvant chemotherapy.

NCT ID: NCT06235164 Active, not recruiting - Clinical trials for Locally Advanced Gastric Cancer

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Start date: January 1, 2019
Phase:
Study type: Observational

To evaluate the safety and effectiveness of laparoscopic gastrectomy (LG) following neoadjuvant immunochemotherapy (nICT)

NCT ID: NCT05610332 Not yet recruiting - Clinical trials for Locally Advanced Gastric Cancer

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types

NCT ID: NCT05545436 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Start date: September 20, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, open, exploratory clinical study to evaluate the efficacy of carrelizumab (PD-1) combined with chemotherapy (SOX/XELOX) as neoadjuvant therapy and to observe the changes of tumor immune microenvironment in patients with locally advanced gastric or gastroesophageal junction cancer (T3-4NXM0).

NCT ID: NCT05528367 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.

NCT ID: NCT05524974 Not yet recruiting - Clinical trials for Locally Advanced Gastric Cancer

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

NCT ID: NCT05141747 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Start date: January 19, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive /HER2-low locally advanced or metastatic gastric/ gastroesophageal junction cancer.

NCT ID: NCT04792515 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer

CCWSA/OAFLAG
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the efficacy and safety of camrelizumab in combination with SOX and/or apatinib in the treatment of locally advanced gastric cancer or gastroesophageal junction adenocarcinoma.The primary endpoint was pathologic complete response (PCR).In addition, secondary efficacy endpoints include R0 resection rate, objective response rate (ORR), and 1-year progression-free survival rate (PFSR) . They were set to demonstrate the therapeutic benefit of camrelizumab combined with SOX in patients 。

NCT ID: NCT03961373 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer

Neo-D2plus
Start date: November 5, 2018
Phase: Phase 3
Study type: Interventional

In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.

NCT ID: NCT03322969 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

For patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of <50% as the criterion of treatment change. Sixty patients will be enrolled to randomize into two groups:receiving modified chemotherapy and receiving the original chemotherapy.